[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100625091":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":21,"centralContacts":22,"locations":32,"responsibleParty":52,"collaborators":21,"id":54,"slug":55,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":58,"acronym":59,"eligibilityCriteria":60,"healthyVolunteers":56,"sex":61,"minAge":62,"maxAge":21,"enrollmentInfo":63,"targetDuration":21,"studyType":66,"phases":67,"briefSummary":69,"conditions":70,"keywords":72,"overallStatus":34,"whyStopped":21,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":86},{"fullName":5,"class":6},"Institute of Oncology Ljubljana","OTHER",[8],{"label":9,"type":6,"description":10,"interventionNames":11},"High risk breast cancer patients","Adult women with inflammatory breast cancer (stage IIID) and non-inflammatory triple negative and HER2+ subtype (stage IIB to IIIA-C) with adequate health status for neoadjuvant systemic treatment",[12],"Diagnostic Test: Liquid biopsy",[14],{"type":15,"name":16,"description":17,"armGroupLabels":18,"otherNames":19},"DIAGNOSTIC_TEST","Liquid biopsy","Additional liquid biopsy to monitor disease",[9],[20],"ctDNA",null,[23,28],{"name":24,"role":25,"phone":26,"phoneExt":21,"email":27},"Klavdija Korošec","CONTACT","00386 1 5879 639","kkorosec@onko-i.si",{"name":29,"role":25,"phone":30,"phoneExt":21,"email":31},"Neza Gros","00386 1 5879 014","ngros@onko-i.si",[33],{"facility":5,"status":34,"city":35,"state":21,"zip":36,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"RECRUITING","Ljubljana","1000","Slovenia","SI",{"type":40,"coordinates":41},"Point",[42,43],14.50513,46.05108,{"lat":43,"lon":42},[46,50],{"name":47,"role":25,"phone":48,"phoneExt":21,"email":49},"Cvetka Grašič Kuhar, MD","0038615879090","cgrasic@onko-i.si",{"name":47,"role":51,"phone":21,"phoneExt":21,"email":21},"PRINCIPAL_INVESTIGATOR",{"type":53,"investigatorFullName":21,"investigatorTitle":21,"investigatorAffiliation":21,"oldNameTitle":21,"oldOrganization":21},"SPONSOR","100625091","studying-the-role-of-circulating-tumor-cell-clusters-in-patients-with-high-risk-early-breast-cancer-study-galia-100625091",false,"NCT07418125","Studying the Role of Circulating Tumor Cell Clusters in Patients With High-risk Early Breast Cancer, Study GALIA","GALIA","Inclusion Criteria:\n\n* Patients with inflammatory breast cancer, regardless of cancer subtype (stage IIID)\n* Patients with non-inflammatory breast cancer: triple-negative and HER2+ subtypes, from stage IIB to IIIA-C\n* Adequate health status for neoadjuvant systemic treatment\n\nExclusion Criteria:\n\n* Inflammatory breast cancer stage IV\n* Luminal A, luminal B subtypes of non-inflammatory breast cancer\n* Stages I-IIA breast cancer\n* Inability to understand or communicate in Slovenian\n* Inability to follow protocol instructions\n* Inappropriate health status for chemotherapy treatment\n* Primary treatment with surgery","FEMALE","18 Years",{"count":64,"type":65},130,"ESTIMATED","INTERVENTIONAL",[68],"NA","CTCs, CTC clusters, and ctDNA may predict treatment response and survival in high-risk breast cancer, including IBC.",[71],"Breast Cancer",[73,20,74,75,76],"breast cancer","liquid biopsy","circulating tumor cell","circulating tumor cluster","2026-02-10",{"date":79,"type":80},"2026-02-18","ACTUAL",{"date":82,"type":80},"2024-02-07",{"date":84,"type":65},"2028-12-31",{"name":5,"class":6},1]